Valneva has met its revenue growth target for 2024, fending off slower-than-expected sales for the chikungunya vaccine Ixchiq. The French vaccine specialist posted total revenues of €169.6m ($ ...

The company has a market cap of $548.51 million, a PE ratio of -51.92 and a beta of 1.98. Valneva has a 12-month low of $3.62 and a 12-month high of $9.50. The company has a current ratio of 2.78 ...

If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older The European Commission (EC) will now review ...

Valneva Trading Down 5.9 % Valneva stock opened at $7.44 on Friday. The stock has a market cap of $604.57 million, a PE ratio of -57.23 and a beta of 1.98. Valneva has a 52 week low of $3.62 and a ...

H.C. Wainwright lowered the firm’s price target on Valneva (VALN) to $17 from $18 and keeps a Buy rating on the shares following the Q4 report. The firm cites reduced sales estimates for Ixchiq ...

Saint-Herblain (France), March 3, 2025 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today announced that its senior management will participate at upcoming investor ...

The positive CHMP opinion is supported by positive six-month adolescent Phase 3 data which Valneva reported in May 2024 2. These data, collected through a study in Brazil funded by the Coalition ...

More information is available at www.valneva.com. This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to business ...

The Danish company’s chikungunya vaccine, Vimkunya, has now crossed the FDA finish line, heating up the competition with Valneva by countering with a label that covers a broader population.

This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to business partnerships and the progress, timing, results and completion of ...

Ratings for Valneva VALN were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...